Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
2027. jún. 30.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)
2027. jan. 31.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
2026. dec. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities.
2026. nov. 4.· Current treatment options in oncology· PUBMED
Publikáció
Claudin 18.2 as a specific diagnostic marker for pulmonary invasive mucinous adenocarcinoma.
2026. nov. 4.· Pathology, research and practice· PUBMED
Publikáció
Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2-Expressing Gastric Cancer.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics.
2026. nov. 2.· Molecular pharmaceutics· PUBMED
Vizsgálat
Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma.
2026. nov. 1.· Anticancer research· PUBMED
Publikáció
CLDN18.2-targeted CAR-NK cells suppress gastric cancer growth in preclinical models.
2026. okt. 30.· Biochemical pharmacology· PUBMED
Publikáció
CLDN18.2 ADCs "A Real Step Forward" for Stomach Cancer.
2026. okt. 27.· Cancer discovery· PUBMED
Publikáció
CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target.
2026. okt. 22.· Frontiers in pharmacology· PUBMED
Publikáció
TRACE-CLDN: An Integrated Computational Pathology Framework for Tumor-Restricted Quantification of CLDN18.2 Expression Burden from H&E Whole-Slide Images in Intrahepatic Cholangiocarcinoma.
2026. okt. 21.· Journal of imaging informatics in medicine· PUBMED
Publikáció
Claudin 18.2: from a tight junction protein to a breakthrough target in solid tumor immunotherapy.
2026. okt. 21.· Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals· PUBMED
Publikáció
Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials.
2026. okt. 8.· Investigational new drugs· PUBMED
Publikáció
ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.
2026. okt. 1.· Annals of surgical oncology· PUBMED
Publikáció
Retrospective Analysis of Zolbetuximab-Associated Hypoalbuminemia in Claudin 18.2-Positive Advanced Gastric Cancer.
2026. okt. 1.· Cancer reports (Hoboken, N.J.)· PUBMED
Vizsgálat
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
2026. szept. 30.· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Repurposing Gastric Cancer Biomarkers for Mucinous Ovarian Carcinoma: ERBB2 and Claudin 18.2 as Therapeutic Targets.
2026. szept. 28.· International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists· PUBMED
Publikáció
Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.
2026. szept. 25.· Medical oncology (Northwood, London, England)· PUBMED
Publikáció
CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy.
2026. szept. 25.· Frontiers in molecular medicine· PUBMED
Vizsgálat
QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ
2026. szept. 24.· PHASE3 · RECRUITING· CTGOV
Publikáció
Correction: Deep learning prediction of MSI/dMMR, EBV, HER2, PD-L1, and CLDN18.2 status directly from hematoxylin and eosin-stained slides in gastric and gastroesophageal junction adenocarcinoma: a systematic review.
2026. szept. 22.· Frontiers in oncology· PUBMED
Publikáció
CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids.
2026. szept. 18.· Biochemical and biophysical research communications· PUBMED
Publikáció
Retrospective analysis of Claudin 18.2 expression in 64 patients with advanced gastrointestinal peritoneal disease: a potential therapeutic target for high-grade appendiceal mucinous carcinoma.
2026. szept. 18.· Journal of clinical pathology· PUBMED
Publikáció
Claudin 18.2 Expression and Outcomes in Resected Gallbladder and Biliary Tract Adenocarcinomas: A Pilot Clinicopathologic Study.
2026. szept. 18.· International journal of surgical pathology· PUBMED
Vizsgálat
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2026. szept. 17.· PHASE3 · RECRUITING· CTGOV
Publikáció
Deep learning prediction of MSI/dMMR, EBV, HER2, PD-L1, and CLDN18.2 status directly from hematoxylin and eosin-stained slides in gastric and gastroesophageal junction adenocarcinoma: a systematic review.
2026. szept. 9.· Frontiers in oncology· PUBMED
Publikáció
Spatial transcriptomics reveals club cell features and strong CLDN18 expression along the mucinous pathway to invasive mucinous adenocarcinoma.
2026. szept. 8.· The Journal of pathology· PUBMED
Publikáció
Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.
2026. szept. 7.· Gut· PUBMED